---
figid: PMC6767051__IJC-145-1179-g002
figtitle: Cell cycle‐non specific mechanisms for the resistance to CDK4/6 inhibitors
organisms:
- Homo sapiens
- Mus musculus
- Caenorhabditis elegans
organisms_ner:
- Mus musculus
- Homo sapiens
- Caenorhabditis elegans
- Drosophila melanogaster
pmcid: PMC6767051
filename: IJC-145-1179-g002.jpg
figlink: /pmc/articles/PMC6767051/figure/ijc32020-fig-0002/
number: F2
caption: 'Cell cycle‐non specific mechanisms for the resistance to CDK4/6 inhibitors.
  (a) Overexpression of various factors which are upstream of the cell cycle, such
  as FGFR, PI3K/AKT/mTOR, and AP‐1, act as bypass pathways for the progression of
  the cell cycle, resulting in decreased efficacy of CDK4/6 inhibitors. Loss of ER
  dependence also drives cells to escape CDK4/6 inhibition. (b) TGF‐β induces the
  expression of several transcription factors involved in EMT via Smad and the PI3K/AKT/mTOR
  pathway. The cyclin‐CDK complex phosphorylates and suppresses Smad 3, recovering
  cell cycle arrest. In addition, inhibition of cyclin D activates autophagy, leading
  to the reversal of cell cycle arrest mediated by CDK4/6 inhibitors. CDK4/6 inhibitors
  may activate various immune‐related genes, which may also play a role in the development
  of resistance. Abbreviations: FGF2, fibroblast growth factor 2; FGFR1, fibroblast
  growth factor receptor 1; ER, estrogen receptor; TGF‐β, transforming growth factor
  β; MEK, Mitogen‐activated protein kinase; ERK, extracellular signal‐regulated kinases;
  PI3K, phosphatidylinositide 3‐kinases; mTOR, mammalian target of rapamycin; PDK1,
  3‐phosphoinositide‐dependent protein kinase‐1; AP‐1, Activator protein 1; EMT, epithelial‐mesenchymal
  transition; NFAT, Nuclear factor of activated T‐cells; IL‐2, Interleukin‐2; DNMT,
  DNA methyltransferase. [Color figure can be viewed at wileyonlinelibrary.com]'
papertitle: 'Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer:
  A review.'
reftext: Kamal Pandey, et al. Int J Cancer. 2019 Sep 1;145(5):1179-1188.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9609247
figid_alias: PMC6767051__F2
figtype: Figure
redirect_from: /figures/PMC6767051__F2
ndex: 51cbca00-dedd-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6767051__IJC-145-1179-g002.html
  '@type': Dataset
  description: 'Cell cycle‐non specific mechanisms for the resistance to CDK4/6 inhibitors.
    (a) Overexpression of various factors which are upstream of the cell cycle, such
    as FGFR, PI3K/AKT/mTOR, and AP‐1, act as bypass pathways for the progression of
    the cell cycle, resulting in decreased efficacy of CDK4/6 inhibitors. Loss of
    ER dependence also drives cells to escape CDK4/6 inhibition. (b) TGF‐β induces
    the expression of several transcription factors involved in EMT via Smad and the
    PI3K/AKT/mTOR pathway. The cyclin‐CDK complex phosphorylates and suppresses Smad
    3, recovering cell cycle arrest. In addition, inhibition of cyclin D activates
    autophagy, leading to the reversal of cell cycle arrest mediated by CDK4/6 inhibitors.
    CDK4/6 inhibitors may activate various immune‐related genes, which may also play
    a role in the development of resistance. Abbreviations: FGF2, fibroblast growth
    factor 2; FGFR1, fibroblast growth factor receptor 1; ER, estrogen receptor; TGF‐β,
    transforming growth factor β; MEK, Mitogen‐activated protein kinase; ERK, extracellular
    signal‐regulated kinases; PI3K, phosphatidylinositide 3‐kinases; mTOR, mammalian
    target of rapamycin; PDK1, 3‐phosphoinositide‐dependent protein kinase‐1; AP‐1,
    Activator protein 1; EMT, epithelial‐mesenchymal transition; NFAT, Nuclear factor
    of activated T‐cells; IL‐2, Interleukin‐2; DNMT, DNA methyltransferase. [Color
    figure can be viewed at wileyonlinelibrary.com]'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tgfb1
  - Ltbp1
  - Fgf2
  - Mtor
  - Akt1
  - Smad2
  - Smad3
  - Smad4
  - Pten
  - Cdk6
  - Cdk4
  - ras
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Pdk1
  - Pdpk1
  - Cdk2
  - Ephb2
  - Mapk1
  - Zeb2
  - Zeb1
  - Twist1
  - Itk
  - Slc22a3
  - Jun
  - Fos
  - Dnmt1
  - Il2
  - pr
  - Pik3ca
  - da
  - Mdk
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - TGFB1
  - TGFB2
  - TGFB3
  - FGF13
  - MTOR
  - AKT1
  - AKT2
  - AKT3
  - SMAD2
  - SMAD3
  - SMAD4
  - PTEN
  - E2F1
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - E2F8
  - CCND1
  - CCND2
  - CCND3
  - CDK6
  - CDK4
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PDK1
  - PDPK1
  - CCNE1
  - CCNE2
  - CDK2
  - EPHB2
  - MAPK1
  - MAPK3
  - ZEB2
  - ZEB1
  - TWIST1
  - ITK
  - SLC22A3
  - JUN
  - FOS
  - FOSB
  - JUNB
  - JUND
  - DNMT1
  - DNMT3A
  - DNMT3B
  - DNMT3L
  - NFATC1
  - NFATC2
  - NFATC3
  - NFATC4
  - NFAT5
  - IL2
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - SMAD1
  - SMAD5
  - SMAD6
  - SMAD7
  - SMAD9
  - CUX1
  - SART3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - cdk-4
  - pdk-1
  - cdk-2
  - dpp
  - gbb
  - put
  - mav
  - bnl
  - Tor
  - Akt
  - Smox
  - Med
  - ebi
  - E2f2
  - E2f1
  - CycD
  - rb
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - CycE
  - Erk7
  - rl
  - twi
  - ea
  - Jra
  - kay
  - AP-1gamma
  - Mt2
  - Nmt
  - NFAT
  - btl
  - htl
  - Mad
  - l(1)G0020
  - Taf4
  - Rpn2
  - Sap-r
  - nAChRalpha2
  - Dsor1
  - Mtk
  - es
  - Estrogen
  - Cancer
  - Lung cancer
---
